The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The prognostic factors associated with long-term survival in the patients with synchronous oligometastatic esophageal adenocarcinoma.
 
Masaaki Iwatsuki
No Relationships to Disclose
 
Kazuto Harada
No Relationships to Disclose
 
Xuemei Wang
No Relationships to Disclose
 
Manoop S. Bhutani
No Relationships to Disclose
 
Brian Weston
No Relationships to Disclose
 
Jeffrey H Lee
Honoraria - Boston Scientific
Consulting or Advisory Role - Boston Scientific
Research Funding - Olympus
Travel, Accommodations, Expenses - Boston Scientific
 
Quynh Nguyen
No Relationships to Disclose
 
Wayne Lewis Hofstetter
No Relationships to Disclose
 
Irene Thomas
No Relationships to Disclose
 
Jane E. Rogers
No Relationships to Disclose
 
Hideo Baba
Honoraria - Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Johnson & Johnson (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Jaffer A. Ajani
Honoraria - Aduro Biotech; Bristol-Myers Squibb; Lilly; Merck
Consulting or Advisory Role - American Cancer Society; BeiGene; Bristol-Myers Squibb; Insys Therapeutics; Merck; Vaccinogen
Research Funding - Amgen; Bristol-Myers Squibb; Delta-Fly Pharma; Gilead Sciences; Lilly/ImClone; Merck; Novartis; Roche/Genentech; Taiho Pharmaceutical; Takeda
Patents, Royalties, Other Intellectual Property - I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly